MOA | Jotup

Moa Reveals Data on Next-Generation Herbicides with New Modes of Action and Progress Towards Field Trials

Retrieved on:

Thursday, January 25, 2024

Herbicide, Therapy, Reuters, Farmer, Health, WSSA, Food security, International, University, Genetics, Omics, Drug discovery, Climate change, Conference, Safety, MOA, Agriculture

The trials planned in the northern and southern hemispheres will cover multiple lead molecules derived from new herbicide modes of action (MOAs).

Key Points:

The trials planned in the northern and southern hemispheres will cover multiple lead molecules derived from new herbicide modes of action (MOAs).
Herbicide-resistant weeds threaten food security and agricultural productivity, and are a major problem for growing numbers of farmers across the world.
“The need for innovation to develop next-generation herbicides to overcome weed resistance to current herbicides is becoming ever more apparent,” says Dr Xavier Jacq, Chief Scientific Officer of Moa Technology.
At Moa we are advancing a growing pipeline of novel herbicides including bioherbicides towards field trials at pace.

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

Retrieved on:

Monday, January 22, 2024

Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

Key Points:

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

Retrieved on:

Thursday, December 7, 2023

Telecanthus, DED, Quality of life, Quinze-Vingts National Ophthalmology Hospital, Uveitis, Tears, MOA, Pain, Diabetic retinopathy, Inflammation, OCS, Patient, Safety, Pharmaceutical industry

The Phase 2b RELIEF trial is a multi-center, randomized, double-masked, vehicle-controlled trial evaluating the safety and efficacy of licaminlimab for the treatment of signs and symptoms in moderate- to-severe DED.

Key Points:

The Phase 2b RELIEF trial is a multi-center, randomized, double-masked, vehicle-controlled trial evaluating the safety and efficacy of licaminlimab for the treatment of signs and symptoms in moderate- to-severe DED.
Furthermore, the trial will evaluate if patients with a specific genetic biomarker identified in a prior trial respond better to licaminlimab.
The trial was designed after several trials with licaminlimab in DED and Uveitis demonstrated positive findings.
Riad Sherif, M.D., Chief Executive Officer of Oculis, remarked: “We are very pleased to have achieved First Patient First Visit (FPFV) in the RELIEF trial as planned.

BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Retrieved on:

Wednesday, December 6, 2023

NAFLD, Risk, NASH, MOA, Non-alcoholic fatty liver disease, Small RNA, Michigan Medicine, Diabetes, Bullfrog, Obesity, University, Fatty liver disease, University of Michigan, DSM-IV codes, Artificial intelligence, Machine learning, SPTBN1, Medical device

GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action (MOA). The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.

Key Points:

The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.
Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes.
Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.
“The market for obesity drugs is projected to exceed $77 billion by 2030 , and pharmaceutical companies around the world have recognized the importance of targeting multiple pathways to treat this condition,” said Vin Singh, CEO of BullFrog AI.

Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment

Retrieved on:

Tuesday, December 5, 2023

MOA, Principal, Pain, Chronic pain, Therapy, Diabetic neuropathy, TRPV1, Temperature, CNS, SOC, NESS, Pharmaceutical industry

BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.

Key Points:

BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.
The dual mechanism of action (MOA) of BSEN760 underlies the compound’s exquisite potency and synergistic activity in dampening sensory neuron hyperexcitability.
As such, BSEN760 may enter the market with comparable, potentially better, efficacy vs. SOC, and a much improved safety profile.
These, and other data, support the Company’s efforts toward full preclinical development of BSEN760 and IND submission by Q1 2025.

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Retrieved on:

Thursday, November 30, 2023

Marketing, IBD, Failure, Adalimumab, Risankizumab, MOA, Gastroenterology, Physician, Ustekinumab, HCP, Ulcerative colitis, Injection, UC, RealTime, JAK, Patient, Celltrion, Upadacitinib, Pharmaceutical industry

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

Key Points:

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on:

Tuesday, November 28, 2023

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points:

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
“Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

Purple Biotech Reports Third Quarter 2023 Financial Results

Retrieved on:

Tuesday, November 21, 2023

REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.

Key Points:

REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.
Recently reported biomarker data demonstrates CM24’s mechanism of action for this important indication in dire need of a more effective drug that prolongs survival,” stated Purple Biotech CEO, Gil Efron.
The increase was mainly due to clinical trials expenses in our CM24 study offset by lower CMC costs in 2023.
A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on:

Monday, November 13, 2023

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points:

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

Plenty Hires VP of Plant Science and Architecture Firm to Advance Development of World's Largest Vertical Farming Research Center

Retrieved on:

Friday, November 10, 2023

LARAMIE, Wyo., Nov. 10, 2023 /PRNewswire/ -- Today, Plenty Unlimited Inc. announced significant updates supporting the development of its new R&D facility, which will be the largest and most technologically advanced indoor vertical farming research center in the world. Following the announcement of the project earlier this year, made possible by Wyoming's largest economic development grant ever given, the project steering committee has achieved its first major milestone, selecting MOA Architecture as the architecture and engineering (A&E) firm. Plenty is also adding top talent to its Laramie leadership team – Sasha Preuss has joined the company as its Vice President of Plant Science. Building on decades of experience heading up biology and biotech programs and labs for some of the world's largest agriculture companies, including Bayer and Monsanto, Sasha is now leading Plenty's team of more than 75 scientists in scaling up the company's R&D work.

Key Points:

Plenty is also adding top talent to its Laramie leadership team – Sasha Preuss has joined the company as its Vice President of Plant Science.
The Laramie research center will significantly expand Plenty's new crop research, which has grown more than 50 different crops in Plenty's 3-D vertical growing system.
The project steering committee conducted a thorough, statewide review and chose MOA Architecture as the A&E firm.
For more information about career opportunities at the Plenty Laramie research center, please visit www.plenty.ag/careers .